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DOI 10.1016/j.ccr.2011.11.025SUMMARYWithin high-grade gliomas, the precise identities and functional roles of stem-like cells remain unclear. In the
normal neurogenic niche, ID (Inhibitor of DNA-binding) genesmaintain self-renewal andmultipotency of adult
neural stem cells. Using PDGF- and KRAS-driven murine models of gliomagenesis, we show that high Id1
expression (Id1high) identifies tumor cells with high self-renewal capacity, while low Id1 expression (Id1low)
identifies tumor cells with proliferative potential but limited self-renewal capacity. Surprisingly, Id1low cells
generate tumors more rapidly and with higher penetrance than Id1high cells. Further, eliminating tumor cell
self-renewal through deletion of Id1 has modest effects on animal survival, while knockdown of Olig2 within
Id1low cells has a significant survival benefit, underscoring the importance of non-self-renewing lineages in
disease progression.INTRODUCTION
High-grade gliomas (WHOGrade III, IV astrocytomas) are among
the most lethal types of solid tumors, with significant cellular and
genetic heterogeneity complicating treatment efforts (Terzis
et al., 2006). Since the discovery of glioma cells with properties
reminiscent of neural stem cells, including the capacity to self-
renew, there has been a great deal of interest in elucidating their
contributions to tumorigenesis. Self-renewal in normal and
tumor stem cells occurs when a cell divides to produce at least
one daughter cell with the same developmental potential as it-
self, thus maintaining multipotency (He et al., 2009). This is in
contrast to proliferation, which refers to cell divisions regardless
of developmental potential (He et al., 2009). Within the subven-
tricular zone (SVZ), normal adult neural stem cells (also referred
to as ‘‘type B cells’’) are rare, slow-cycling and self-renewingSignificance
High-grade gliomas are typified by poor therapeutic response
esis, we identify and isolate two distinct stem- and progenitor-
glioma cells self-renew, giving rise to consistent proportions o
renewal capacity but retain proliferative potential. Although
tumorigenic compared to Id1high cells. Further, inhibiting the bH
prolongs the survival of tumor-bearingmice, while eliminating s
have important implications for therapeutic strategies that se
subclasses of high-grade gliomas.cells that give rise to more rapid cycling transit amplifying cells
(‘‘type C cells’’), which then give rise to more differentiated neu-
roblasts (‘‘type A cells’’) (Doetsch et al., 1997). Glioma stem cells,
likened to type B cells, are defined by their capacity to (1) self-
renew in vitro, (2) transplant tumors in vivo, and (3) generate
tumors that recapitulate the heterogeneity of the parental tumors
(Stiles and Rowitch, 2008). The degree to which glioma stem
cells resemble neural stem cells, and the degree to which the
normal lineage hierarchy is maintained in brain tumors remain
unanswered questions.
The cancer stem cell hypothesis predicts that stem cells are
responsible for tumor initiation and preferentially drive tumor
growth, and indeed, many studies use the term ‘‘glioma-initiating
cell’’ (GIC) interchangeably with ‘‘glioma-stem cell’’ (GSC). How-
ever, whether stem-like cells are uniquely qualified in their ability
to transplant disease, or whether other, more differentiated,and rapid lethality. Using two mouse models of gliomagen-
like tumor cell populations using a single marker, Id1. Id1high
f differentiated lineages, while Id1low cells have limited self-
both populations transplant disease, Id1low cells are more
LH transcription factor Olig2 within Id1low cells significantly
elf-renewal of Id1high cells has modest effects. These results
ek to target stem- or progenitor- like cells within different
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Figure 1. Tumors Can Be Separated into Id1high and Id1low Cell Populations
(A) Tumors were initiated with RCAS-PDGFB in Nestin-tva; Arf/ mice (A–J). Staining with hematoxylin and eosin (H&E) shows high-grade features. Scale
bars = 100 mm.
(B) Immunohistochemistry for Id1 reveals Id1+ cells within the tumor (arrows). Scale bars = 50 mm.
(C) FACS plot from Nestin-tva;Arf/;Id1VenusYFP tumors. Gray line indicates gate for VenusYFP signal.
(D) Id1 immunostaining on sorted Id1low (top) and Id1high (bottom) cells reveals Id1 expression restricted to the Id1high cell population (arrows). Cells were
counterstained with DAPI. Scale bars = 50 mm.
(E) Quantitative RT-PCR reveals enhanced Id1 expression in Id1high compared to Id1low cells.
(F) Quantitative RT-PCR for Olig2, Olig1, Mash1, NG2, Id2, S100b, Math1, Prominin1, Id3, Id4, SSEA-1 from Id1low (gray bars) and Id1high (black bars) sorted cells.
(G) Immunohistochemistry for Olig2 reveals a frequent expression pattern of Olig2+ cells (arrows). Scale bars = 50 mm.
(H) Graph shows percentage of Id1+ and Olig2+ tumor cells from PDGF-driven tumors.
(I) Immunostaining for Id1 (green), Olig2 (red) and spectral analysis showing intensity in red channel and green channels. Scale bars = 50 mm.
(J) Olig2 immunostaining on sorted Id1low (top) and Id1high (bottom) cells reveals Olig2 expression restricted to the Id1low cell population (arrows). Cells were
counterstained with DAPI. Scale bars = 50 mm.
(K) Tumors were initiated with RCAS-KRAS in Nestin-tva; Arf/ mice (K-T). Staining with H&E shows high-grade features. Scale bars = 100 mm.
(L) Immunohistochemistry for Id1 reveals Id1+ cells within the tumor (arrows). Scale bars = 50 mm.
(M) FACS plot from Nestin-tva;Arf/;Id1VenusYFP tumors. Gray line indicates gate for VenusYFP signal.
(N) Id1 immunostaining on sorted Id1low (top) and Id1high (bottom) cells reveals Id1 expression restricted to the Id1high cell population (arrows). Cells were
counterstained with DAPI. Scale bars = 50 mm.
(O) Quantitative RT-PCR reveals enhanced Id1 expression in Id1high compared to Id1low cells.
(P) Quantitative RT-PCR for Olig2, Olig1, Mash1, NG2, Id2, S100b, Math1, Prominin1, Id3, Id4, SSEA-1 from Id1low (gray bars) and Id1high (black bars) sorted cells.
(Q) Immunohistochemistry for Olig2 reveals a frequent expression pattern of Olig2+ cells (arrows). Scale bars = 50 mm.
(R) Graph shows percentage of Id1+ and Olig2+ tumor cells from KRAS-driven tumors.
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Self-Renewal Is Not Essential for Glioma Growthnon-self-renewing lineages possess this capacity, remains
controversial (Alcantara Llaguno et al., 2009; Chow et al.,
2011; Lindberg et al., 2009; Prestegarden and Enger, 2010;
Stiles and Rowitch, 2008). In other types of brain tumors,
including medulloblastoma (Yang et al., 2008) and oligodendro-
glioma (Persson et al., 2010), cell lineages that express progen-
itor markers but are incapable of self-renewal in vitro have been
shown to transplant disease. Further, oligodendrocyte precursor
cells (OPCs) were recently identified as likely cells-of-origin in
a p53/Nf1 mouse model of gliomagenesis, as lineage-analysis
revealed this population to have the most dramatic growth
expansion prior to malignancy (Liu et al., 2011). Adding to the
complexity, it has been hypothesized that more differentiated
cells may dedifferentiate and acquire a stem cell phenotype
during the course of tumorigenesis (Kang et al., 2006). How fre-
quently this occurs in vivo and whether the acquisition of self-
renewal and ‘‘stemness’’ is a requisite for tumorigenic potential
requires further investigation.
Critical to the analysis of high-grade gliomas is the identifica-
tion of markers to definitively isolate and functionally charac-
terize the distinct lineages. CD133 (Prominin-1) is the most
common antigen used to identify glioma stem cells, but studies
have shown that both CD133+ and CD133- cells can self-renew
and generate histologically distinct tumors (Beier et al., 2007;
Chen et al., 2010; Cle´ment et al., 2009; Wang et al., 2008),
arguing against CD133 as a specific marker of glioma stem
cells. Other studies have used the side population (SP) to define
the stem-cell fraction, although this also identifies a heteroge-
neous population of both self-renewing and non self-renewing
lineages (Broadley et al., 2011). The ID (Inhibitor of DNA-binding)
genes are dominant negative regulators of basic helix-loop-helix
transcription factors (Perk et al., 2005) with established roles
in embryonic stem cell self-renewal (Romero-Lanman et al.,
2011; Ying et al., 2003). Following development, Id1 continues
to regulate self-renewal and differentiation in multiple somatic
stem cell populations, including adult neural stem cells. High
levels of Id1 identify type B adult neural stem cells within neuro-
genic niches, and Id1 and Id3 are required to maintain the self-
renewal capacity of this cell population (Nam and Benezra,
2009). During lineage commitment, Id1 protein levels decrease
as progenitor markers become more highly expressed (Nam
and Benezra, 2009). While Id1 expression is low to absent in
nonneurogenic regions of the normal adult brain, Id1 expression
is upregulated inmultiple subtypes of human andmouse gliomas
(Anido et al., 2010; Vandeputte et al., 2002). Because high levels
of Id1 identify self-renewing typeB cells in the normal neurogenic
niche, we hypothesized that high levels of Id1 could similarly
identify glioma cells with a stem-cell phenotype.
Large-scale sequencing projects have identified alterations
that frequently occur in human high-grade gliomas, including
PDGFRA amplification (13%), alterations in RTK/RAS/PI(3)K
signaling (88%) and CDKN2A/Arf homozygous deletion or muta-
tion (49%) (Network, 2008). This has led to the generation of sub-
classes based upon specific genomic and proteomic signatures(S) Immunostaining for Id1 (green), Olig2 (red) and spectral analysis showing inte
(T) Olig2 immunostaining on sorted Id1low (top) and Id1high (bottom) cells reveals
counterstained with DAPI. Scale bars = 50 mm.
Error bars represent mean ± SD. See also Figure S1.(Brennan et al., 2009; Huse et al., 2011; Network, 2008).
Although studies differ with regard to subclass identity and
nomenclature, broadly speaking, tumors with aberrant PDGFR
signaling have been grouped in the Proneural subclass, and
tumors with mutation and/or deletion of NF1 have been grouped
in the Mesenchymal subclass. The PDGFR/Proneural subclass
has a well-established RCAS/tva-based mouse model, where
adult Nestin-tva;Arf/ mice are stereotaxically injected with
RCAS-PDGFB into the SVZ, generating gliomas with near com-
plete penetrance (Hambardzumyan et al., 2009, 2011). Tumors
can also be initiated using constitutively active mutant KRAS,
as KRAS has been shown to cooperate with tumor suppressor
loss to generate gliomas (Uhrbom and Holland, 2001; Uhrbom
et al., 2005). Tumors driven by either PDGF or KRAS show
a histopathology that closely mimics human tumors, as well
as high-grade features, including pseudopalisading necrosis
and microvascular proliferation (Hambardzumyan et al., 2009,
2011; Uhrbom and Holland, 2001; Uhrbom et al., 2005).
Here, we test a central tenet of the cancer stem cell hypoth-
esis, that self-renewal capacity is required for disease trans-
plantation and is a key predictor of tumor growth potential, in
PDGF- and KRAS-driven murine glioma models.
RESULTS
PDGF- and KRAS-Driven Tumors Can Be Separated
into Id1high and Id1low Cell Populations
As shown in Figures 1A and 1B, tumors initiated with PDGF dis-
played high-grade features and upregulated Id1 expression,
similar to what is observed in human high-grade gliomas (Fig-
ures S1A and S1B available online). In order to isolate and
further characterize live tumor cells with high Id1 expression,
we generated Nestin-tva;Arf/;Id1VenusYFP mice, where endog-
enous Id1 is fused to fluorescent VenusYFP and faithfully reports
endogenous Id1 protein levels (Nam and Benezra, 2009). Fol-
lowing initiation with PDGF, tumors were dissociated and sorted
based on VenusYFP expression into cell populations with high
levels of VenusYFP (further referred to as Id1high) and cell popu-
lations with undetectable levels of VenusYFP (further referred to
as Id1low) (Figure 1C). Post-sort analysis was used to confirm the
absence of VenusYFP signal in the Id1low fraction (Figure S1C)
and Id1high cells were, on average, 0.35% of the total sorted
population, including stromal cells (Figure 1C). Immunostaining
(Figure 1D) and RT-PCR (Figure 1E) confirmed Id1 expression
in freshly sorted Id1high cells and low to undetectable levels of
Id1 expression in freshly sorted Id1low cells. The stem-associ-
ated markers Prominin-1 and Id3 were more highly expressed
in Id1high cells compared to Id1low cells (Figure 1F). In contrast,
multiple progenitor-associated markers, including Olig2, Mash1,
NG2, and Id2 were more highly expressed in Id1low cells com-
pared to Id1high cells (Figure 1F).
Olig2 is known to regulate proliferation in neural progenitors
(Ligon et al., 2007; Sun et al., 2011) and is expressed in multiple
lineages, including type C cells in the normal neurogenic nichensity in red channel and green channels. Scale bars = 50 mm.
Olig2 expression restricted to the Id1low cell population (arrows). Cells were







Figure 2. Id1high Cells Are Characterized by High Self-Renewal Capacity, while Id1low Cells Are Characterized By Limited Self-Renewal
Capacity
(A) Percentage of sorted Id1high and Id1low cells forming primary tumorspheres from PDGF-driven tumors (10 cells/ml; *p = 2.37 3 107).
(B) Percentage of sorted Id1high (gray bars) and Id1low (black bars) cells forming secondary, tertiary, quaternary and quinary tumorspheres from PDGF-driven
tumors (1 cell/well; *p = 0.026, **p = 0.0084, ***p = 0.01, ****p = 0.007).
(C) Tumorsphere diameter was measured after 7 days in vitro for Id1low (n = 60) and Id1high (n = 128) tumorspheres (*p = 1.663 105) from PDGF-driven tumors.
(D) Id1high cells were used to generate secondary, tertiary, quaternary and quinary tumorspheres, which were then differentiated and the percentage of cells from
individual tumorspheres that expressed GFAP, Tuj1, and O4 were quantified.
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expressed in all subtypes of malignant glioma (Ligon et al.,
2004), leading us to more closely examine Olig2 expression in
our model. Within PDGF-driven tumors, we observed high levels
of Olig2 expression (Figure 1G), consistent with what is observed
in human gliomas (Figures S1D and S1E) including those from
the PDGFR subclass (Verhaak et al., 2010). By IHC, 5.2% of
tumor cells had detectable levels of Id1 expression and 84.6%
of cells had detectable levels of Olig2 expression (Figure 1H).
Sorted Id1high cells make up a subset of the total Id1-expressing
population, as Id1 is expressed in varying levels in both tumor
cells and stromal cells. Importantly, Olig2 and Id1 showed
a largely mutually exclusive expression pattern (Figure 1I). Of
Id1-expressing tumor cells, only 6.1% showed some level of
Olig2 expression (Figure S1F). In the normal neurogenic niche,
Id1 levels decrease and progenitor markers increase as cells
transition from a type B cell to a type C cell phenotype (Nam
and Benezra, 2009), and this population overlap within tumors
may reflect a similar phenomenon. Importantly, we did not detect
Olig2 protein expression in the sorted Id1high population, and
found significant Olig2 protein expression in the sorted Id1low
population (Figure 1J).
In order to test the generality of our results, we examined
tumors driven by RCAS mutant KRAS using Nestin-tva; Arf/;
Id1VenusYFP mice. As shown in Figures 1K and 1L, KRAS-driven
tumors also displayed high-grade features and upregulated Id1
expression. By FACS, Id1high cells represented, on average,
0.67% of the total sorted population including stromal cells (Fig-
ure 1M). Immunostaining (Figure 1N) and RT-PCR (Figure 1O)
confirmed Id1 expression in freshly sorted Id1high cells and low
to undetectable levels of Id1 expression in freshly sorted Id1low
cells. Id1high and Id1low cells from KRAS-driven tumors showed
a lineage-marker profile similar to what was observed from
PDGF-driven tumors (Figure 1P). Compared to PDGF-driven
tumors, KRAS-driven tumors had more Id1-expressing cells by
IHC and fewer Olig2-expressing cells, with 23.4% of tumor cells
expressing Id1 and 66.3% of tumor cells expressing Olig2 (Fig-
ures 1Q and 1R). Coimmunostaining for Id1 and Olig2 again re-
vealed a largely mutually exclusive expression pattern (Figure 1S).
Importantly, we did not detect Olig2 protein expression in the
sorted Id1high cells, and found significant Olig2 protein expression
in the sorted Id1low cells (Figure 1T). Thus, in both PDGF- and
KRAS-driven tumors, sorted Id1high cells were characterized by
high levels of the neural stem cell marker Id1, and an absence of
common progenitor-associated markers. While Id1low cells repre-
sented heterogeneous tumor bulk, they were characterized by
high levels of Olig2 and other progenitor-associated markers.
We further characterized the expression of Id1 and several
lineage markers using human glioma tissue microarrays(E) Representative images of tumorspheres generated from Id1high cells that were
images, 50 mm for insets. Cells were counterstained with DAPI in fluorescent ima
(F) Number of adherent colonies formed after 7 days in vitro from Id1low cells (n =
(G) Diameter of adherent colonies measured after 3 days (p = 0.38; n = 17), 5 d
(black bars) compared to Id1high cells (gray bars).
(H) Percentage of phosphohistone H3 expressing cells within adherent colonies
(p = 0.75; n = 16) or 7 days (*p = 0.014; n = 35).
(I) Representative images of Id1low and Id1high adherent colonies after 5 or 7 days
main images, 50 mm for insets.
Error bars represent mean ± SD. See also Figure S2.(TMAs). Here, we found that a subset of Id1-expressing cells
also expressed the putative stem-cell marker CD133, although
we observed both CD133+/Id1- and CD133-/Id1+ cells (Fig-
ure S1G). While Id1 and Olig2 showed a largely exclusive
expression pattern in the PDGF- and KRAS-driven murine
models, we identified two distinct groups from the human
TMAs: one group showed a largely exclusive expression pat-
tern between Id1 and Olig2, while the other group showed
a high-degree of overlap between the two proteins (Figures
S1D and S1E). We speculate that differences may exist in the
Id1/Olig2 lineage relationship, and expression of stem and
progenitor cells generally, within distinct subtypes of high-grade
gliomas.
Id1high Tumor Cells Have Stem Cell Properties, while
Id1low Tumor Cells Resemble Progenitor Cells
Wehypothesized that high levels of Id1would identify tumor cells
with a stem cell phenotype, similar to what is observed in type B
cells of the normal neurogenic niche. To assess the self-renewal
capacity of Id1high and Id1low glioma cells, we plated cells at
clonal density in the presence of epidermal growth factor (EGF)
and fibroblast growth factor (FGF) and characterized tumor-
sphere formation and colony formation in vitro. From PDGF-
driven tumors, freshly sorted Id1high cells showed a 12.8-fold
enhancement in primary tumorsphere formation compared to
Id1low cells (Figure 2A; 10 cells/ml). Similar results were obtained
when cells were plated to form tumorspheres prior to sorting to
eliminate stroma and then dissociated, sorted into Id1high and
Id1low populations and replated to form tumorspheres (Fig-
ure S2A; 10 cells/ml). Primary tumorspheres were dissociated
and plated at clonal density (1 cell/well) over serial passages.
From Id1high primary tumorspheres, 15.06% of single cells
formed secondary tumorspheres, of which 11.62% of single
cells formed tertiary tumorspheres, 8.82% of single cells formed
quaternary tumorspheres, and 7.10% of single cells formed
quinary tumorspheres (Figure 2B). By contrast, from Id1low
primary tumorspheres, 0.33% of single cells formed secondary
tumorspheres, of which 0.625% of single cells formed tertiary
tumorspheres, with no generation of tumorspheres over addi-
tional passages (Figure 2B). Id1high cells generated tumor-
spheres that were marginally larger than those generated from
Id1low cells (Figure 2C). Similar results were observed in KRAS-
driven tumors, where Id1high cells showed a 7.5-fold enhance-
ment in primary tumorsphere formation compared to Id1low cells
(Figure S2B; 10 cells/ml). From Id1high primary tumorspheres,
7.67% of cells formed secondary tumorspheres, 1.85% of cells
formed tertiary tumorspheres, and 0.267% of cells formed
quaternary tumorspheres (plated 0.5 cells/ml; Figure S2C). By
contrast, we were unable to generate secondary tumorspheresdifferentiated and stained for GFAP, Tuj1, and O4. Scale bars = 100 mm for main
ges.
14) compared to Id1high cells (n = 24) (0.5 cells/ml; *p = 5.29 3 107).
ays (p = 0.04; n = 27) and 7 days (*p = 6.39 3 105; n = 14) from Id1low cells
from Id1low cells (black bars) compared to Id1high cells (gray bars) after 5 days
stained for H3P (green) and counterstained with DAPI. Scale bars = 100 mm for
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(Figure S2C).
Id1low secondary tumorspheres, as well as Id1high secondary,
tertiary, quaternary, and quinary tumorspheres from the PDGF-
driven model were plated under conditions to favor differen-
tiation, and the resultant progeny were quantified.While undiffer-
entiated tumorspheres showed low to absent expression of
GFAP, O4, and Tuj1 (Figures S2D and S2E), individual Id1high
secondary tumorspheres primarily generated GFAP-expressing
astrocytes upon differentiation, with less frequent but consis-
tent generation of O4-expressing oligodendrocytes and Tuj1-
expressing neurons (Figures 2D and 2E; Figure S2F). Essentially
all individual Id1high tumorspheres showed similar percentages
of cells expressing thesemarkers. We also observed similar pro-
portions of GFAP-, O4-, and Tuj1-expressing cells from Id1high
tumorspheres at tertiary, quaternary, and quinary passages (Fig-
ure 2D; Figure S2F), consistent with these populations under-
going self-renewal events, rather than physical events such as
in vitro fusion. The fact that the Id1high population primarily differ-
entiated into GFAP-expressing cells is also consistent with
studies showing a role for Id1 in restraining neural differentiation
(Ying et al., 2003). Id1low secondary tumorspheres, by contrast,
showed a high degree of variability with regards to their differen-
tiation potential: 37.5% primarily generated GFAP-expressing
cells, 43.75% primarily generated Tuj1-expressing cells, and
18.75% generated roughly equal numbers of GFAP- and Tuj1-
expressing cells (n = 16; Figure S2G). The generation of
O4-expressing cells was sporadic, found within approximately
18% of differentiated Id1low secondary tumorspheres (Fig-
ure S2G). Thus, Id1high glioma cells displayed a classic stem-cell
phenotype in vitro, while Id1low glioma cells, depleted of stromal
cells, were found to possess limited self-renewal capacity.
Id1low and Id1high cells derived from PDGF-driven tumors were
also plated at clonal density (0.5 cells/ml) as adherentmonolayers
using the same mitogenic conditions as in the nonadherent
tumorsphere assays. Id1high cells generated colonies more
frequently than Id1low cells (Figure 2F), and generated colonies
that weremarginally larger than those generated from Id1low cells
(Figure 2G), paralleling our tumorsphere data (Figures 2A–2C).
We did not observe significant differences in expression of
cleaved caspase-3 between colonies generated from Id1low
and Id1high cells (data not shown), nor didwe observe differences
in H3P expression after 5 days in vitro (Figures 2H and 2I). Id1high
colonies did show approximately 2-fold greater H3P expression
at 7 days in vitro suggesting a modest proliferative advantage
(Figures 2H and 2I). Nonetheless, both Id1low and Id1high cells
were capable of proliferation, suggesting that the dramatic
differences in tumorsphere formation between the Id1low and
Id1high cell populations were due largely to differences in self-
renewal capacity, as opposed to an inability of the Id1low cells
to proliferate under the conditions used in our assays.
Id1low Cells More Efficiently Transplant Disease than
Id1high Cells
We next probed the capacity of Id1low and Id1high glioma cells to
transplant disease by injecting 1.03 103 freshly sorted cells into
the cortex of adult Nude/NCr host mice. From PDGF-driven
tumors, both Id1low and Id1high cells were capable of generating
high-grade gliomas (Figures 3A and 3B). However, Id1low cells16 Cancer Cell 21, 11–24, January 17, 2012 ª2012 Elsevier Inc.generated tumors more quickly and with higher penetrance:
mice injected with 1.0 3 103 Id1low cells had a median survival
of 35.5 days compared to mice injected with 1.0 3 103 Id1high
cells, which had amedian survival of 62 days (Figure 3A). Tumors
were generated in 73.7% of mice injected with 1.0 3 103 Id1low
cells compared to 46.7% of mice injected with 1.0 3 103 Id1high
cells (Figure 3A). We were unable to generate tumors with
1.0 3 103 cells from either Id1low or Id1high cells when they
were plated in vitro prior to transplantation (data not shown).
Plating cells in vitro also led to changes in Id1 and Olig2 expres-
sion (Figures S3A–S3C), and we therefore injected freshly sorted
cells in all experiments, allowing us to avoid in vitro selection
bias and analyze the lineages in a minimally perturbed state.
We also performed the same experiments using 1.03 103 Id1high
or Id1low cells isolated from KRAS-driven tumors. Here, 52.6%of
mice injected with 1.0 3 103 Id1low cells developed high-grade
tumors, with a median survival of 37 days (Figure 3C), while 1
of 19 mice (5.3%) injected with 1.03 103 Id1high cells developed
a low-grade tumor with a survival of 119 days (Figure 3C). There-
fore, in both PDGF- and KRAS-driven tumors, Id1low cells
generated tumors more quickly and with higher penetrance
than Id1high cells.
Tumors initiated with either Id1low or Id1high cells expressed
Nestin, GFAP, and Tuj1 (Figures S3D and S3E), although the
majority of tumor cells expressed Olig2 (Figures 3B and 3D).
The fact that Id1high cells did not express Olig2 upon isolation in-
dicates that Id1-expressing tumor cells were generating Olig2-
expressing tumor cells in vivo. This is consistent with studies in
the normal SVZ, which show that type B cells can generate oligo-
dendrocyte lineages (Jackson et al., 2006; Menn et al., 2006),
and with the observation that Id1high B-type cells give rise
to Id1low (Mash1+, Olig2+) progenitor cells (Nam and Benezra,
2009). Surprisingly, both Id1low and Id1high cells generated
tumors with Id1 expression (Figures 3B and 3D).
To determine the source of Id1 expression in tumors initiated
with Id1low cells, we injected 1.0 3 103 Id1low cells from the
PDGF-driven model into the cortex of ubc-GFP;NOD-SCID
mice, which express GFP in all cells (Figure 4A). Immunostaining
for Id1 revealed that Id1 expression was restricted to GFP ex-
pressing cells (Figure 4B). We did not observe Id1-expressing/
GFP-nonexpressing cells (Figure 4C), indicating that the Id1 ex-
pressing cells were in fact host-derived. In contrast to Id1,
immunostaining for Olig2 did not colocalize with GFP, indicating
that the Olig2 expressing cells were coming from the initiating
cell population (Figures 4D and 4E). We also observed recruit-
ment using cells isolated from the KRAS-driven model (Fig-
ure S4A). These data are consistent with studies in other model
systems showing that cells recruited from the normal brain
parenchyma can contribute to glioma heterogeneity (Assanah
et al., 2006). To determine whether Id1 expression in the re-
cruited population was important for tumor growth, we injected
1.0 3 103 Id1low cells from PDGF-driven tumors into the cortex
of Id1/mice. These mice also developed tumors (Figure S4B),
indicating that Id1 expression in the recruited cells was not
essential for tumorigenic potential. Further, both Id1low and
Id1high cells led to recruitment of similar numbers of cells (Fig-
ure S4C), suggesting that the differences in tumor initiation
between Id1low and Id1high cells were not due to their relative




Figure 3. Id1low Cells Transplant Disease More Efficiently than Id1high Cells
(A) Kaplan-Meier analysis comparingmice injectedwith 1.03 103 Id1low cells (n = 19; red line) or 1.03 103 Id1high cells (n = 15; blue line) fromPDGF-driven tumors.
Chart shows percentage of mice that developed tumors and median survival.
(B) Representative images of H&E, Olig2 and Id1 immunohistochemistry for tumors generated with either Id1low (bottom) or Id1high (top) cells from PDGF-driven
tumors. Scale bars = 100 mm for main images, 50 mm for insets.
(C) Kaplan-Meier analysis comparingmice injectedwith 1.03 103 Id1low cells (n = 19; red line) or 1.03 103 Id1high cells (n = 19; blue line) fromKRAS-driven tumors.
Chart shows percentage of mice that developed tumors and median survival.
(D) Representative images of H&E, Olig2 and Id1 immunohistochemistry for tumors generated with Id1low (bottom) or Id1high (top) cells from KRAS-driven tumors.
Scale bars = 100 mm for main images, 50 mm for insets. See also Figure S3.
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tumorigenesis and therefore this type of conversion could not
explain the tumorigenic potential of the Id1low cell population.
Inhibiting the Self-Renewal Capacity of Id1high Cells Has
Modest Effects on Tumor Growth
To determine how a reduction in self-renewal capacity would
impact tumor growth, we generated Nestin-tva;Arf/ mice
with the following genotypes: Id1+/+;Id3+/+, Id1/;Id3+/+, and
Id1/;Id3+/. As shown in Figure 5, loss of Id1 led to dramatic
reductions in tumor cell self-renewal capacity. Id1/;Id3+/+
and Id1/;Id3+/ mice had a 5- to 10-fold reduction in primary
tumorsphere formation compared to Id1+/+;Id3+/+ mice (Fig-
ure 5A; 10 cells/ml). From Id1+/+;Id3+/+ mice, 19.8% of cells
formed secondary tumorspheres, compared to 0.067% of cells
from Id1/;Id3+/+ mice and 0.21% of cells from Id1/;Id3+/
mice (Figure 5B; 1 cell/well). Id1+/+ Id3+/+ tumorspheres primarily
differentiated into GFAP-expressing cells, with less frequent but
consistent generation of O4- and Tuj1-expressing cells (Figures
5C and 5D). We observed similar proportions of GFAP-, O4-, andTuj1-expressing cells from secondary and tertiary tumorspheres
(Figures 5C and 5D), and a pattern of differentiation closely
paralleling that of Id1high tumorspheres (Figures 2D and 2E).
Cells from Id1+/+;Id3+/+ and Id1/;Id3+/ mice were also
plated as adherent monolayers at clonal density (0.5 cells/ml).
Cells plated from Id1/;Id3+/ tumors generated fewer adherent
colonies than cells plated from Id1+/+;Id3+/+ tumors (Figure 5E)
and while the average H3P expression in Id1/;Id3+/ colonies
was slightly lower compared to Id1+/+;Id3+/+ colonies at 7 days
in vitro, these differences were not statistically significant (Fig-
ure 5F). Thus, both cell populations were capable of proliferation
in vitro.
The reduction in self-renewal capacity with Id loss mirrors
the effects of Id loss in normal adult neural stem cells (Nam
and Benezra, 2009). However, we observed only modest effects
of Id loss on tumor-free survival (Figure 5G). Similar effects on
tumor-free survival were observed following conditional loss of
Id1 in Nestin-tva;Arf/ mice: after coinjection of RCAS-PDGFB
and RCAS-Cre, Id1+/+;Id3+/+ mice had a median survival of
28 days and Id1flox/flox;Id3+/+ mice had a median survival ofCancer Cell 21, 11–24, January 17, 2012 ª2012 Elsevier Inc. 17
Figure 4. Id1low Cells Do Not Revert to an Id1-
Expressing State In Vivo
(A) Schematic illustrating the injection of Id1low (nonfluo-
rescent) cells into ubc-GFP;NOD-SCID host mice.
(B) Two representative images showing coimmunostain-
ing for GFP and Id1. Note the presence of Id1+/GFP+ cells
(arrowheads). Tissue was counterstained with DAPI. Scale
bars = 50 mm.
(C) Percentage of tumor cells that were Id1+/GFP+
compared to Id1+/GFP- (n = 4 mice, >900 Id1+ cells).
(D) Two representative images showing coimmunostain-
ing for GFP and Olig2. Tissue was counterstained with
DAPI. Scale bars = 50 mm.
(E) Percentage of tumor cells that were Olig2+/GFP+
compared to Olig2+/GFP- (n = 4 mice, >900 Olig2+ cells).
Error bars represent mean ± SD. See also Figure S4.
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Id3 show redundancy of function at the level of self-renewal
(Nam and Benezra, 2009). We therefore probed the effects
of combined Id1 and Id3 loss to eliminated potential compen-
sation between Id proteins. Nestin-tva;Arf/ Id1flox/flox; Id3/
mice injected with RCAS-PDGFB and RCAS-Cre had a
median survival no different from control animals (28 days;
Figure S5).
Id1low tumor cells showed significant growth potential in vivo
(Figure 3), and we hypothesized that inhibiting the growth of
the Id1low population might confer a more significant survival
benefit. As Olig2 is a known mediator of glioma growth in cell
line models, we inserted an H1 promoter driving Olig2 shRNA
downstream of PDGFB in the RCAS vector (Figures S6A
and S6B). Using RCAS-PDGFB;Olig2-shRNA or RCAS-PDGFB;
shRNA-Control constructs to initiate tumors, we found that
Olig2 knockdown significantly increased tumor-free survival
(Figure 6A). Olig2 knockdown was confirmed in tumors that
were removed at early time points from presymptomatic mice
(Figure 6B). Tumors that grew out from the Olig2 shRNA condi-
tion expressed Olig2 (Figure 6C), consistent with previous
reports showing a significant role for Olig2 in human and mouse
gliomas (Ligon et al., 2007; Mehta et al., 2011). To further explore
the relationship between Id1 and Olig2, primary mouse glioma
cells were transiently transfected with Id1 siRNA, Olig2 siRNA
or Control siRNA. Knockdown of Id1 did not affect Olig2 expres-
sion levels, and knockdown of Olig2 did not affect Id1 expression18 Cancer Cell 21, 11–24, January 17, 2012 ª2012 Elsevier Inc.levels (Figure S6C), suggesting that neither
gene directly represses the other in our model
system.
To begin to explore the role of Id1 and stem-
like cells in human high-grade gliomas, we
analyzed survival data from The Cancer Ge-
nome Atlas for each of the identified subtypes
(Verhaak et al., 2010) based on Id1 expression
for patients diagnosed with primary GBMs.
Patients were subdivided into those with high
Id1 expression (top 50%) and those with low
Id1 expression (bottom 50%), compared to the
unfiltered data set (Figures 7A–7D). Within the
Proneural subclass, patients with high Id1expression had a median survival of 22.015 months, com-
pared to patients with low Id1 expression, which had a median
survival of 6.015 months (Figure 7D). No significant differences
in survival were observed for the Classical, Mesenchymal and
Neural subtypes when subdivided by Id1 expression (Figures
7A–7C). As the PDGF-driven murine model most closely
mimics the Proneural subclass, this human data, while cor-
relative, is consistent with our finding that low Id1 expres-
sion identifies a more aggressive tumor cell population in this
subtype.
DISCUSSION
Self-renewal is the defining characteristic of both normal and
cancer stem cells. It has been postulated that glioma cells with
stem cell properties preferentially transplant disease and con-
tribute disproportionately to tumor growth compared to other,
more differentiated lineages. Our results argue against this strin-
gent interpretation of the cancer stem cell hypothesis. Using
a marker of normal adult neural stem cells, we identified glioma
cells with high self-renewal capacity and compared their tumor-
igenic potential to that of low self-renewing lineages. We found
that in PDGF- and KRAS- driven mouse glioma models, both
cell populations were capable of transplanting disease, and cells
with low self-renewal capacity were actually more tumorigenic.
Thus, GICs cannot be exclusively identified by self-renewal or
‘‘stemness.’’
Figure 5. Id1-Loss Significantly Impacts Tumor Cell Self-Renewal but Has Only Modest Effects on Tumor-Free Survival
(A) Percentage of cells forming primary tumorspheres from PDGF-driven tumors (10 cells/ml) using Nestin-tva;Arf/ ;Id1/;Id3+/+ mice (n = 4; *p = 0.0017),
Nestin-tva;Arf/ ;Id1/;Id3+/ mice (n = 5; **p = 0.001) and Nestin-tva;Arf/ ;Id1+/+;Id3+/+ mice (n = 6).
(B) Percentage of cells forming secondary tumorspheres from PDGF-driven tumors (0.5 cells/ml) using Nestin-tva;Arf/ ;Id1/;Id3+/+ mice (n = 3; *p = 0.0044),
Nestin-tva;Arf/ ; Id1/;Id3+/ mice (n = 5; **p = 0.0003) and Nestin-tva;Arf/ ;Id1+/+;Id3+/+ mice (n = 4).
(C) Percentage of cells from secondary or tertiary tumorspheres that differentiated into GFAP, Tuj1, and O4 expressing cells. Tumorspheres were generated from
Nestin-tva;Arf/ ;Id1+/+;Id3+/+ mice.
(D) Representative images of tumorspheres generated from Id1+/+;Id3+/+ cells, differentiated, and stained for GFAP, Tuj1, and O4. Scale bars = 100 mm for main
images, 50 mm for insets. Cells were counterstained with DAPI in fluorescent images.
(E) Number of adherent colonies formed after 7 days in vitro from Id1+/+;Id3+/+ cells compared to Id1/;Id3+/ cells (0.5 cells/ml; *p = 4.98 3 108).
(F) Percentage of phosphohistone H3 (H3P) expressing cells within adherent colonies from Id1+/+ Id3+/+ compared to Id1/ Id3+/ mice after 7 days in vitro
(p = 0.44).
(G) Kaplan-Meier analysis comparing Nestin-tva;Arf/ ;Id1+/+;Id3+/+ mice (n = 27) with Nestin-tva;Arf/ ;Id1/;Id3+/+ mice (n = 23; *p = 0.0003) and Nestin-
tva;Arf/ ;Id1/;Id3+/ mice (n = 14; **p = 0.0003). Tumors were initiated with PDGF. Chart shows median survival.
Error bars represent mean ± SD. See also Figure S5.
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Unlike the clearly defined, marker restricted lineages that exist in
the hematopoietic system, stem and progenitor cells in the
normal neurogenic niche and in brain tumors remain relatively
ill-defined, complicating efforts to assign functional roles to
these cell populations. While many studies use CD133 (Pro-
minin 1) to identify glioma stem cells, CD133- cells can also
self-renew, suggesting that CD133 expression alone does not
definitively identify glioma stem cells. High Id1 expression iden-
tifies type B cells in the normal neurogenic niche, and Id1 levelsdecrease gradually during lineage commitment (Nam and
Benezra, 2009). Reversion from an Id1low to an Id1high state is
never observed, and we have therefore taken advantage of the
Id1-VenusYFP knockin strain to isolate cells with high levels of
Id1 within murine gliomas, and specifically identify the stem-
like fraction.
We define self-renewal capacity by the ability of cells to form
multipotent tumorspheres of consistent progeny over serial pas-
sages when plated at clonal density in serum-free, adherent-
free conditions. While definitive assays for self-renewal remainCancer Cell 21, 11–24, January 17, 2012 ª2012 Elsevier Inc. 19
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Figure 6. Targeting Id1low Progenitor-Like Cells via Knockdown of Olig2 Shows a Significant Survival Benefit
(A) Kaplan-Meier analysis comparing Nestin-tva;Arf/ mice injected with RCAS-PDGFB-shRNA Control or RCAS-PDGFB-Olig2 shRNA. Chart shows
percentage of mice that developed tumors and median survival.
(B) Olig2 immunostaining from tumors (dotted line) generated with shRNA Control or Olig2 shRNA. Tumors were analyzed from pre-symptomatic mice. Tissue
was counterstained with DAPI. Scale bars = 100 mm.
(C) H&E and Olig2 immunohistochemistry from tumors generated with shRNA Control or Olig2 shRNA. Tumors were analyzed when mice became symptomatic.
Scale bars = 100 mm. See also Figure S6.
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tumorsphere under defined conditions has historically been
used as an in vitro measure of self-renewal (Galli et al., 2004;
Pastrana et al., 2011; Singh et al., 2003, 2004). A recent review
by Pastrana et al. (2011) highlights a number of important
considerations for the design and interpretation of sphere-
formation assays. Importantly, we sorted fluorescent cells dir-
ectly from transgenic mice, eliminating issues related to anti-
body labeling and antigen presentation. We also plated cells
in identical mitogenic conditions and used clonal densities to
reduce the likelihood of aggregations. Further, we confirmed
the multipotency and proliferation potential of our cell popula-
tions. Under these experimental conditions, Id1high glioma cells
were characterized by high self-renewal capacity, giving rise to
tumorspheres with similar proportions of differentiated progeny
over multiple passages, and thus maintaining multipotency.
Id1high cells also gave rise to heterogeneous tumors in vivo,
fulfilling the criteria of glioma stem cells. By contrast, Id1low
glioma cells were characterized by low self-renewal capacity,
generating tumorspheres with variable proportions of differen-
tiated progeny. Undifferentiated Id1low cells also expressed
progenitor markers (including high levels of Olig2), and had
the ability to generate heterogeneous tumors in vivo, making
them more characteristic of multipotent progenitors. It has
been hypothesized that, within tumors, Olig2 may represent a
transition from a type B cell to a type C cell, although Olig2
is also expressed in more differentiated lineages (Ligon et al.,
2007). Taken together, our data suggest that Id1high glioma
cells resemble type B cells, at or near the top of the line-
age hierarchy, while Id1low cells more closely resemble type
C cells.20 Cancer Cell 21, 11–24, January 17, 2012 ª2012 Elsevier Inc.Tumor Cell Self-Renewal Does Not Predict Tumor
Growth Potential
Our data show that Id1low glioma cells resembling type C cells
have greater tumorigenic potential than Id1high glioma cells
reminiscent of type B cells in PDGF- and KRAS-driven tumors
(Figure 8). Although it is important to note that both pop-
ulations were capable of transplanting disease, we were sur-
prised to find that Id1low cells generated tumors more
quickly and with higher penetrance, indicating that self-renewal
did not cosegregate with tumorigenic potential. Thus, the
ability of a glioma cell to proliferate even while changing state
(as seen in the Id1low population) appears in this model system
to be compatible with the ability to transplant disease
efficiently.
Id1high cells generated tumors with high levels of Olig2 expres-
sion, which is consistent with acquisition of Olig2 in the Id1high
population being a critical factor in its tumorigenic potential,
and previous studies have indeed shown an essential role for
Olig2 in gliomagenesis (Ligon et al., 2007). While Id1high cells
were capable of generating tumors with Olig2 expression, Id1low
cells never reverted to an Id1-expressing state. Therefore, the
lineage hierarchy of the normal neurogenic niche, which
proceeds unidirectionally from stem cell to progenitor cell, was
also maintained in our murine glioma models. We found no
evidence for interconversion from an Id1low progenitor state to
an Id1high stem-like state, although such dedifferentiation has
been reported in in vitro systems (Kondo and Raff, 2000) and
may occur under other oncogenic conditions. Thus, Id1low cells
need not dedifferentiate and acquire Id1 expression in order to
transplant disease. Our results also suggest that Id1high cells
present in PDGF-driven gliomas likely arise from stem cell pools,
A B
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Figure 7. ID1 Expression Levels Correlate with Survival of Human Patients within the Proneural Subclass of High-Grade Gliomas
Kaplan Meier analysis based on ID1 expression using data from each of the four TCGA identified subtypes of primary GBM: (A) Classical (p = 0.20), (B)
Mesenchymal (p = 0.43), (C) Neural (p = 0.65), and (D) Proneural. For the proneural subtype, the medium survival of patients with low and high Id1 expressing
tumors are 6.015 months and 22.015 months, respectively (p < 0.0001).
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Id1high state.
The Id1-expressing cells observed in tumors generated from
Id1low cells were derived exclusively from the host, and Fom-
chenko et al. (2011) recently found significant roles for recruited
cells in PDGF-driven murine gliomas. These cells were shown to
aid in disease transplantation and had the capacity to become
independent of the initiating oncogene (Fomchenko et al.,
2011). We found that Id1 expression in the recruited population
was not required for tumor growth, which was largely unaffected
when Id1low cells were transplanted into an Id1/ background.
Our Id1-knockout studies further support the idea that Id1
expression and self-renewal capacity is not essential for tumor
growth. If tumors were dependent upon self-renewal for their
growth potential, we would expect that knockout of Id1, which
significantly impacted tumorsphere formation, would have
a greater impact on overall survival than observed. Our Olig2-
knockdown studies lend further support to the notion that
progenitor cell lineagesmaymake greater contributions to tumor
growth in PDGF-driven gliomas.
ID Genes in High-Grade Gliomas
We have isolated glioma cells that express high levels of Id1, and
find that they represent a highly self-renewing population of
tumor cells, allowing us to probe the role of self-renewal in glioma
growth, rather than the role of ID genes in glioma biology gener-
ally. However, multiple ID genes are upregulated in high-gradegliomas and implicated in glioma pathogenesis (Vandeputte
et al., 2002), and ID genes are known to have roles in tumor
biology beyond self-renewal, including neoangiogenesis and
regulation of cell-cycle (Perk et al., 2005). Recently, Anido et al.
(2010) isolated a CD44high cell population from human patient
derived glioma cells characterized by high levels of Id1 expres-
sion, TGF-ß-responsiveness and stem-like properties. These
data are consistent with our results showing a role for Id1 in
glioma cell self-renewal, and points to TGF-ß as a likely upstream
regulator of Id1. While Id3 cosegregated with Id1 in our assays,
Id2 and Id4 did not. It is likely that Id1/Id3 and Id2 and Id4 are
expressed in different cell types and possess different functional
roles depending on the specific tumorigenic context. While the
effects of loss of Id1/3 on overall survival were modest in our
model systems, it is possible that targeting additional Id proteins
would yield amoredramatic effect, as thismay impactboth stem-
and progenitor-like cell populations. In fact, recent studies indi-
cate that combined loss of Id1, Id2, and Id3 impacts glioma cell
self-renewal as well as proliferation, leading to a significant delay
in tumor progression (A.I., unpublishedobservations). Our finding
that multiple lineages are capable of transplanting disease
suggests that targeting a single cell population alone may not
yield optimal therapeutic effects in these tumor subtypes.
Relevance to Human Disease
This work raises a number of questions regarding the origin
and propagation of human high-grade gliomas. We know thatCancer Cell 21, 11–24, January 17, 2012 ª2012 Elsevier Inc. 21
Figure 8. Proposed Model of High and Low Self-Renewing Lineages
in Gliomagenesis
(A) Model depicting Id1high cells, Id1low/Olig2+ cells, and mature lineages.
(B) Comparison of Id1high cells and Id1low/Olig2+ cells in disease trans-
plantation. Arrow represents recruitment of Id1-expressing cells to the tumor
bulk.
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Id1 and Olig2 upregulation (Anido et al., 2010; Ligon et al., 2007;
Vandeputte et al., 2002) and studies exploring at the effects of
Olig2 knockdown in primary human glioma cells also show
a significant delay in tumor development upon orthotopic trans-
plantation (Mehta et al., 2011), consistent with our mouse knock-
down experiments. Further, data from TCGA suggest that, within
the Proneural subclass, high Id1 expression is associated with
a better survival outcome. As gliomas are highly heterogeneous
tumors that can be classified intomultiple subtypes, further work
will be required to determine the role of self-renewing, stem-like
cells in tumors generated with other mutations and amplifica-
tions as well as the relative response of these different cell
populations to radiation and chemotherapy. It is possible that
stem-like and progenitor-like cells have different contributions
to tumorigenesis depending on the oncogenic context, and
a careful analysis of these cell populations in additional tumor
subtypes will be important for determining the optimal cell pop-
ulations for therapeutic targeting.
EXPERIMENTAL PROCEDURES
In Vivo Models
Nestin-tva; Arf/ mice (Hambardzumyan et al., 2009), Id1VenusYFP mice,
Id1flox/flox mice (Nam and Benezra, 2009), and Id1/ mice (Lyden et al.,22 Cancer Cell 21, 11–24, January 17, 2012 ª2012 Elsevier Inc.1999) have been described. ubc-GFP mice were crossed with NOD-SCID
mice to generate ubc-GFP;NOD-SCIDs. All mouse experiments were ap-
proved by MSKCC’s Institutional Animal Care and Use Committee (IACUC).
Immunostaining
The following primary antibodies were used: Id1 (Biocheck), Id3 (Biocheck),
Olig2 (Millipore), MAP2 (Millipore), GFAP (Millipore), Tuj1 (mouse, Millipore),
Tuj1 (rabbit, Covance), O4 (Millipore), Nestin (BD Biosciences), phosphory-
lated histone H3 (H3P; Sigma), Cleaved Caspase 3 (Cell Signaling Tech-
nology), CD133 (Miltenyi Biotech), and GFP (Abcam).
Flow Cytometry
Cells were sorted for VenusYFP expression with PI exclusion at our FACS
facility using a MoFlo cell sorter (Cytomation).
In Vitro Tumorsphere Assays
Tumors were papain digested (Worthington Biochemical), triturated and cells
were plated for in vitro analysis in Neurocult Stem Cell Basal Media with Prolif-
eration Supplements, 20 ng/ml EGF, 10 ng/ml FGF, and 2 mg/ml heparin (Stem
Cell Technologies).
TCGA Kaplan-Meier Analysis
Id1 expression data were retrieved from the MSKCC cBio Cancer Genomics
Portal (http://www.cbioportal.org/public-portal/). Patients were subdivided
into high Id1 expression (top 50%) and low expression (bottom 50%) for
analysis.
Statistics
Kaplan-Meier survival curves were generated with Prism software. All
experiments were carried out in triplicate or greater. All p values are two-tailed
and p values < 0.05 were considered significant. Data are shown as
mean ± SD.
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